Amarin to Report Fourth Quarter and Year-End 2013 Results and Host Conference Call on February 27, 2014
February 24 2014 - 6:00AM
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company
focused on the commercialization and development of therapeutics to
improve cardiovascular health, today announced that it will host a
conference call with members of Amarin senior management to discuss
the company's fourth quarter and year-end 2013 financial results
and provide an operational update on Thursday, February 27, 2014,
at 4:30 p.m. ET. The conference call will follow the anticipated
release of the company's fourth quarter and year-end 2013 financial
results earlier that day.
The conference call can be heard live via the investor relations
section of the company's website at www.amarincorp.com, or via
telephone by dialing 877-407-8033 within the United States or
201-689-8033 from outside the United States. A replay of the call
will be made available for a period of two weeks following the
conference call. To hear a replay of the call, dial 877-660-6853
(inside the United States) or 201-612-7415 (outside the United
States). A replay of the call will also be available through the
company's website shortly after the call. For both dial-in numbers
please use conference ID 13576006.
About Amarin
Amarin Corporation plc is a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health. Amarin's product development program
leverages its extensive experience in lipid science and the
potential therapeutic benefits of polyunsaturated fatty acids.
Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is
a patented, ultra pure omega-3 fatty acid product comprising not
less than 96% EPA and is available by prescription. For more
information about Vascepa visit www.vascepa.com. For more
information about Amarin visit www.amarincorp.com.
Availability of other information about
Amarin
Investors and others should note that we communicate with our
investors and the public using our company website
(www.amarincorp.com), our investor relations website
(http://www.amarincorp.com/investor-splash.html), including but not
limited to investor presentations and investor
FAQs, Securities and Exchange Commission filings, press
releases, public conference calls and webcasts. The information
that we post on these channels and websites could be deemed to be
material information. As a result, we encourage investors, the
media, and others interested in Amarin to review the information
that we post on these channels, including our investor relations
website, on a regular basis. This list of channels may be updated
from time to time on our investor relations website and may include
social media channels. The contents of our website or these
channels, or any other website that may be accessed from our
website or these channels, shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933.
CONTACT: Amarin contact information:
Joseph Bruno
Investor Relations and Corporate Communications
Amarin Corporation
In U.S.: +1 (908) 719-1315
investor.relations@amarincorp.com
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024